How should testosterone replacement therapy be initiated and monitored in a patient with confirmed testosterone deficiency?

Testosterone Replacement Therapy: Initiation and Monitoring

Initiate testosterone replacement therapy only after confirming both low testosterone levels (total testosterone <300 ng/dL on two separate early morning measurements) AND the presence of compatible symptoms, then aim for mid-normal range testosterone levels (450-600 ng/dL) with systematic monitoring at 3-6 months and annually thereafter. 1, 2, 3

Diagnostic Requirements Before Initiation

Before starting therapy, you must establish:

• Two separate early morning total testosterone measurements <300 ng/dL (some guidelines use <350 ng/dL), drawn on different days 3, 4
• Presence of symptoms: reduced libido, erectile dysfunction, fatigue, reduced energy/endurance, mood changes, decreased muscle mass, or infertility 3, 5
• Physical signs when present: reduced body hair, gynecomastia, small/soft testes, reduced muscle mass 3
• Measure LH and FSH to distinguish primary from secondary hypogonadism 5

Critical pitfall: Do not treat based on symptoms alone or a single testosterone measurement. The 2018 AUA guideline emphasizes that nearly one-third of men receiving testosterone therapy do not meet diagnostic criteria 3.

Baseline Safety Assessment

Before initiating therapy, obtain:

• Hematocrit: Baseline hematocrit >50% (or >48% per 2018 guidelines) is a relative contraindication; these men require further evaluation before considering therapy 1, 2
• PSA and digital rectal examination: For men ≥40 years old with baseline PSA >0.6 ng/mL, or men 55-69 years old who choose prostate monitoring 1, 2
• Prostate cancer screening: Absolute contraindication if active prostate or breast cancer 5
• Cardiovascular assessment: Recent major cardiovascular events or uncontrolled heart failure are contraindications 5

Formulation Selection and Dosing Strategy

The goal is physiologic replacement with stable symptoms, not maximizing testosterone levels. 6

Injectable Testosterone (Enanthate/Cypionate)

• Target mid-normal range (450-600 ng/dL measured midway between injections) 1, 2
• Adjust if: Mid-interval testosterone >700 ng/dL or <400 ng/dL 1
• Injection frequency: Weekly dosing often provides more stable levels than every-two-week dosing; consider twice-weekly or more frequent dosing if patients report symptom cycling, early peak-related symptoms (acne, mood changes, fluid retention), or late-cycle hypogonadal symptoms 6

Transdermal Gels

• Assess testosterone 2-8 hours after application, after ≥1 week of treatment 2
• Adjust dose to achieve mid-normal range
• Critical warning: Patients must cover application sites and wash skin before skin-to-skin contact to prevent transfer 7

Other Formulations

• Transdermal patches: Check levels 3-12 hours after application 1, 2
• Buccal tablets: Check immediately before or after fresh system application 1, 2
• Injectable testosterone undecanoate: Measure just before next injection; adjust interval to maintain mid-normal nadir levels 2

Monitoring Protocol

Initial Follow-up (3-6 months after initiation)

Assess all of the following 1, 2:

1. Symptom response: Sexual function, energy, mood, muscle mass
2. Testosterone level:
   • Timing depends on formulation (see above)
   • Target mid-normal range (450-600 ng/dL)
3. Hematocrit:
   • Stop therapy immediately if hematocrit >54% until it decreases to safe level
   • Evaluate for hypoxia and sleep apnea
   • Reinitiate with reduced dose 1, 2
4. PSA and digital rectal examination (for men ≥40 years with baseline PSA >0.6 ng/mL, or men 55-69 years choosing monitoring) 2

Annual Monitoring

Continue checking annually 1, 2:

• Symptom assessment and adverse effects
• Testosterone level
• Hematocrit
• PSA and digital rectal examination (age-appropriate)

Triggers for Urological Referral

Obtain immediate urological consultation if 1, 2:

• PSA increase >1.4 ng/mL within any 12-month period
• Confirmed PSA >4.0 ng/mL at any time
• Prostatic abnormality on digital rectal examination
• PSA velocity >0.4 ng/mL/year (using 6-month level as reference, applicable if >2 years of data) 1
• Substantial worsening of lower urinary tract symptoms 2

Special Monitoring Considerations

Bone Density

Measure BMD of lumbar spine and/or femoral neck after 1-2 years in men with osteoporosis or low-trauma fracture 1, 2

Formulation-Specific Adverse Effects

Monitor at each visit 1:

• Injectable esters: Mood or libido fluctuations, rarely cough after injections
• Gels: Skin-to-skin transfer risk (advise covering sites, washing before contact)
• Patches: Skin reactions at application site
• Buccal tablets: Taste alterations, gum/oral mucosa irritation

Key Clinical Pitfalls

1. Nearly half of men on testosterone therapy never have follow-up testosterone levels checked 3 - this is unacceptable practice
2. Dose redistribution should be considered before dose escalation for injectable testosterone 6
3. Context matters for lab interpretation: Document ester type, dose, concentration, route, injection interval, timing of last injection, and timing of bloodwork 6
4. Hematocrit >54% requires immediate cessation, not just monitoring 1, 2
5. The 2018 Endocrine Society guideline represents the most recent comprehensive update, refining earlier 2010 and 2006 recommendations with updated cardiovascular and prostate safety data 2